This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics' Deal Begs $18 Million Questions

But if Bianco is so confident about Stellar 3, then why is he directing the company to raise cash three months or so before Xyotax's moment of glory? And, presumably, before Cell Therapeutics' stock price moves significantly higher? And why is Cell Therapeutics raising money at such a steep discount to the market price?

These are questions I'd be asking if I owned the stock. It might be that Cell Therapeutics is feeling the pressure of its less-than-stellar financial position. The company's $103 million in cash and marketable securities at the end of the third quarter is only expected to last into the first half of 2005. The company is also carrying about $190 million in debt on its balance sheet.

Tuesday, the company said it will receive another $25 million plus $5 million in services by selling a royalty stream based on future sales of its drug Trisenox to Quintiles Transnational. This is the financing move the company told shareholders to expect on its last quarterly conference call, so why do this royalty deal and the stock sale? (On a positive but unrelated note, CEO Bianco finally repaid a delinquent $3.5 million corporate loan plus accrued interest on Oct. 22.)

Whatever the reason for Monday's quickie stock sale, it just doesn't foster confidence coming so soon before the crucial Xyotax data event expected at the end of March. Cell Therapeutics' shareholders had better hope that the Xyotax Stellar 3 trial is a success, because if it fails, a stock sale at a 19% discount to the market price will be the least of their worries.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $1.22 -2.40%
FB $105.47 0.06%
GOOG $750.27 0.28%
TSLA $231.11 0.64%
YHOO $32.95 -0.63%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs